TOP HEADLINES

Featured Story

  • Pfizer's Prevnar gets $2B boost with CDC nod in older adults

    Let the uptake begin. Pfizer has snagged the CDC panel recommendation for Prevnar 13 it's been looking for--a nod for use in adults over the age of 65. And that should result in a sales lift that analysts say could touch $2 billion in peak additional sales potential--for now.

Clinical failure for Merck KGaA's cancer vaccine dents subpopulation hopes

Back in 2012, researchers flagged some positive results for patient subgroups in a flunked trial of Merck KGaA's cancer vaccine. But now, the vaccine has hit another snag, failing to hit its primary endpoint--as well as three secondary endpoints--in a Japanese trial, partner Oncothyreon said Monday in an SEC filing.

FDA sets decision date for Pfizer's MenB candidate

Pfizer and Novartis are in a dead heat to become the first vaccinemaker to roll out a meningitis B vaccine for the U.S. market. But the New York pharma giant just became the first of the two to snag a decision date from the FDA, which says it will have an answer on Pfizer's candidate within the next 6 months.

Glaxo quietly edges toward Ebola vaccine but clinical barriers remain

As Africa continues to experience the most severe Ebola outbreak in the disease's short history, the World Health Organization has deemed it ethical to offer unregistered interventions as potential treatments or preventive therapies, including investigational vaccines.

Sanofi's high-dose Fluzone beats standard-dose version in protecting seniors

Sanofi appealed to the FDA to change the labeling of its high-dose Fluzone vaccine to reflect superior efficacy data in people aged over 65, and now it has fresh trial results to back up its case that Fluzone High-Dose provides better protection in individuals in this age group compared to traditional flu jabs.

Health Canada signs off on GSK's plans to improve its flu vaccine plant

GlaxoSmithKline has submitted its plans to whip its troubled Quebec flu vaccine plant into shape to Health Canada, and the regulator says the action outline is up to snuff.

MORE NEWS

From Our Sister Sites

FierceMedicalDevices

Further concentrating life science powerhouses around Boston, GE Healthcare Life Sciences will open a new U.S. headquarters in Marlborough, MA. It's expected to house more than 500 employees, including at least 220 new hires.

FiercePharma

No price war on hepatitis C drugs? That would be a disappointment to payers worried about the cost of treating millions of patients with super-expensive, yet highly effective drugs. But to investors, that reassurance sounds really good.